CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $25.82M, above the global median of $18.73M
- FinancialsHigh structural barrier to entry
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.22%
Annual Rate
INR 1.20Paid annual
Payout Ratio
8.9%Sustainable
Last Ex-Dividend
Sep 11, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
96.67BINR1.01B · vs all stocks (USD)
Trailing P/E
42.21xvs Biotechnology peers
Revenue (TTM)
8.86BINR92.30M · vs all stocks (USD)
Profit Margin
26.52%vs Biotechnology peers
Beta
0.6160xvs all stocks
52-Week Change
-11.56%vs all stocks
Market Capitalization
96.67BINR1.01B · vs all stocks (USD)
Enterprise Value
96.18BINR1.00B · vs all stocks (USD)
Trailing P/E
42.21xvs Biotechnology peers
Forward P/E
29.27xvs Biotechnology peers
PEG Ratio
-1.46xvs Biotechnology peers
Price to Sales (TTM)
11.18xvs Biotechnology peers
Price to Book (MRQ)
7.28xvs Biotechnology peers
Enterprise to Revenue
10.86xvs Biotechnology peers
Enterprise to EBITDA
35.54xvs Biotechnology peers
Gross Margin
53.22%vs Biotechnology peers
Profit Margin
26.52%vs Biotechnology peers
Operating Margin
31.17%vs Biotechnology peers
Return on Assets (TTM)
15.10%vs Biotechnology peers
Return on Equity (TTM)
18.22%vs Biotechnology peers
Revenue (TTM)
8.86BINR92.30M · vs all stocks (USD)
Revenue per Share (TTM)
51.04INRUpdated Sep 29, 2026Quarterly Revenue Growth
-17.40%vs Biotechnology peers
Gross Profit (TTM)
4.86BINR50.67M · vs all stocks (USD)
EBITDA (TTM)
3.97BINR41.36M · vs all stocks (USD)
Net Income (TTM)
2.35BINR24.48M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-14.20%vs Biotechnology peers
Operating Cash Flow (TTM)
3.34BINR34.82M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
2.48BINR25.82M · vs all stocks (USD)
Trailing Annual Dividend Rate
1.20INRUpdated Sep 29, 2026Trailing Annual Dividend Yield
0.22%vs all stocks
Payout Ratio
8.86%vs Biotechnology peers
Revenue
9.47BINRFY2026 · Mar 31, 2026Cost of Goods Sold
4.36BINRFY2026 · Mar 31, 2026Gross Profit
5.12BINRFY2026 · Mar 31, 2026Operating Income
2.70BINR28.15M · vs all stocks (USD)
Pre-tax Income
3.33BINRFY2026 · Mar 31, 2026Income Tax Expense
846.96MINRFY2026 · Mar 31, 2026Net Income
2.48BINRFY2026 · Mar 31, 2026EBIT
3.39BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
3.63BINRFY2026 · Mar 31, 2026Other Operating Expenses
1.44BINRFY2026 · Mar 31, 2026Non-operating Interest Expense
62.39MINRFY2026 · Mar 31, 2026EPS (Basic)
14.29INRFY2026 · Mar 31, 2026EPS (Diluted)
14.29INRFY2026 · Mar 31, 2026Basic Shares Outstanding
173.42MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
173.42MSharesFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
4.64BINRFY2026 · Mar 31, 2026Free Cash Flow
2.45BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
608.57MINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
3.33BINRFY2026 · Mar 31, 2026Other Non-cash Items
-26.51MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
279.58MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
1.07BINRFY2026 · Mar 31, 2026Capital Expenditures
-2.19BINRFY2026 · Mar 31, 2026Purchase of Investments
-4.09BINRFY2026 · Mar 31, 2026Sale of Investments
3.44BINRFY2026 · Mar 31, 2026Other Investing Activity
10.00KINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-2.84BINRFY2026 · Mar 31, 2026Common Dividends Paid
-208.18MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-208.18MINRFY2026 · Mar 31, 2026Shares Outstanding
173.47MSharesUpdated Sep 29, 2026Float Shares
44.91MSharesUpdated Sep 29, 2026% Held by Insiders
76.02%vs all stocks
% Held by Institutions
5.91%vs all stocks
Total Cash (MRQ)
3.23BINR33.70M · vs all stocks (USD)
Total Cash per Share (MRQ)
18.64INRUpdated Sep 29, 2026Total Debt (MRQ)
421.84MINR4.40M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0310xvs Biotechnology peers
Current Ratio (MRQ)
4.21xvs Biotechnology peers
Book Value per Share (MRQ)
78.40INRUpdated Sep 29, 2026Total Assets
16.41BINR171.03M · vs all stocks (USD)
Total Current Assets
9.57BINRFY2026 · Mar 31, 2026Total Liabilities
2.81BINRFY2026 · Mar 31, 2026Total Non-current Assets
6.84BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
537.90MINRFY2026 · Mar 31, 2026Total Current Liabilities
2.27BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
608.57MINRFY2026 · Mar 31, 2026Other Short-term Investments
3.27BINRFY2026 · Mar 31, 2026Accounts Receivable
3.39BINRFY2026 · Mar 31, 2026Inventory
1.87BINRFY2026 · Mar 31, 2026Accounts Payable
569.20MINRFY2026 · Mar 31, 2026Short-term Debt
46.04MINRFY2026 · Mar 31, 2026Other Current Liabilities
19.95MINRFY2026 · Mar 31, 2026Long-term Debt
375.80MINRFY2026 · Mar 31, 2026Common Stock (Book)
346.93MINRFY2026 · Mar 31, 2026Total Shareholders' Equity
13.60BINR141.72M · vs all stocks (USD)
52-Week Low
325.00INRUpdated Sep 29, 202652-Week High
692.90INRUpdated Sep 29, 202652-Week Change
-11.56%vs all stocks
Beta
0.6160xvs all stocks
50-Day MA
584.17INRUpdated Sep 29, 2026200-Day MA
483.80INRUpdated Sep 29, 2026Avg 10-Day Volume
458.72KSharesUpdated Sep 29, 2026Avg 30-Day Volume
471.67KSharesUpdated Sep 29, 2026Diluted EPS (TTM)
13.52INRUpdated Sep 29, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With OCF Coverage And Cash Near Total Debt
Cash on hand covers most or all of its total debt, and cash flow matches reported earnings.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
How is this stock valued?
Drawdown With FCF And Cash Backing
Well below its peak, with three years of positive free cash flow behind it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.63
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $25.82M, above the global median of $18.73MNotable
Levered free cash flow (USD): 25,824,905.36Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Haohai Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
0009K0
Tier 1ProductionApproval-Gated PipelineRuleRisk
Monte Rosa Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sunflower Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sino Medical Sciences Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Wanbang Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pacira BioSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Kanghua Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Dezhan Health Care Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shantou Institute of Ultrasonic Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Harmony Biosciences Holdings, Inc.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedCash Backing With OCF Coverage And Cash Near Total Debt
M&A Research Institute Holdings, Inc.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedDrawdown With FCF And Cash BackingIndustry-Benchmarked Return on Capital ElevatedCash Backing With OCF Coverage And Cash Near Total Debt
Thyrocare Technologies Ltd.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedCash Backing With OCF Coverage And Cash Near Total Debt